Bio Hack

­

From Crawl to Sprint: The Race to Treat NASH

This blog, written by Rosana Kapeller, CSO of Nimbus Therapeutics, is part of the “From the Trenches” feature of LifeSciVC. Early this week, Intercept Pharmaceuticals announced the much awaited design of their Ph. 3 clinical trial of Obeticholic Acid (OCA) in NASH (non-alcoholic steatohepatitis) with liver fibrosis (here). The trial, named REGENERATE, will be the [...]

March 16th, 2016|Bio Hack, Events, In the Know, Lab News, News|Comments Off on From Crawl to Sprint: The Race to Treat NASH